Angel Matthew 4

What Happened
Angel Matthew, listed as a 10% owner of Tempest Therapeutics (TPST), received a grant/derivative award covering 269,621 shares on February 4, 2026. The Form 4 reports the acquisition price as $0.00 and classifies the transaction as an award (derivative), not an open‑market purchase or sale. This is a grant of equity-linked instruments (not an immediate cash transaction or market sale).

Key Details

• Transaction date: 2026-02-04; Form 4 filed: 2026-02-06 (filed within standard reporting window).
• Transaction type/code: Grant/Award (code A), derivative securities for 269,621 shares, reported price $0.00.
• Shares owned after transaction: Not specified in the supplied filing.
• Footnote (F1): 25% of the shares vest on Feb 4, 2027; remaining shares vest in 36 equal monthly installments thereafter, subject to continued service.
• Filing timeliness: Filed two days after the transaction date (appears timely, not marked late).

Context
This was a compensation/award-style grant (derivative), which typically vests over time and is intended for retention or alignment, rather than an immediate expression of buying or selling stock. The reported $0.00 reflects that this was a grant rather than an open-market purchase; the filing does not detail any exercise/strike price or immediate sale of shares. As a 10% owner, Angel Matthew is a material holder—such awards affect insider alignment but are different from outright purchases that retail investors often view as stronger near-term confidence signals.